Status:
UNKNOWN
Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury
Lead Sponsor:
Seoul National University Bundang Hospital
Collaborating Sponsors:
LG Life Sciences
Conditions:
Cancer
Cisplatin Adverse Reaction
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
PHASE3
Brief Summary
Cisplatin is a potent chemotherapeutic agent, however, its nephrotoxicity manifested by acute kidney injury (AKI) often limits applicability. Dipeptidylpeptidase-4 (DPP4) inhibitors are well known to ...
Detailed Description
This study will investigate possible renoprotective effects of DPP4 inhibitor on cisplatin induced acute kidney injury.
Eligibility Criteria
Inclusion
- age \> 18 years
- cancer patients treated with intravenous cisplatin
- written consent
Exclusion
- Diabetes mellitus
- Chronic kidney disease stage IV-V (eGFR \< 30ml/min/1.73m2)
- History of transplantation
- History of acute kidney injury before randomization
- Use of other nephrotoxic agents such as non steroidal anti-inflammatory drugs, aminoglycosides, colistin, vancomycin
- Receiving contrast media during last 72 hours
- Liver disease (bilirubin \> 2 mg/dl, transaminase levels \>2.5 times the upper limit normal)
- Active infection
- Patients with high risks of dehydration owing to poor oral intake
- High blood pressure (\> 180/110 mmHg despite antihypertensive medications)
- Hypersensitivity to Gemigliptin or its excipients
- Low compliance to Gemigliptin treatment
Key Trial Info
Start Date :
December 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2018
Estimated Enrollment :
182 Patients enrolled
Trial Details
Trial ID
NCT02250872
Start Date
December 1 2014
End Date
June 1 2018
Last Update
April 20 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea, 463-707